PHM : Summary for PulteGroup, Inc. Common Stock - Yahoo Finance

U.S. Markets closed

PulteGroup, Inc. (PHM)

NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
19.60-0.25 (-1.26%)
At close: 4:03 PM EST
People also watch:
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close19.85
Bid19.56 x 500
Ask20.30 x 400
Day's Range19.30 - 19.76
52 Week Range14.61 - 22.40
Avg. Volume5,411,839
Market Cap6.48B
PE Ratio (TTM)12.33
Earnings DateN/A
Dividend & Yield0.36 (1.93%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    PulteGroup Announces Quarterly Cash Dividend of $0.09 Per Share

    ATLANTA, Dec. 9, 2016 /PRNewswire/ -- PulteGroup, Inc. (NYSE: PHM) announced today that its Board of Directors has declared a quarterly cash dividend of $0.09 per common share payable January 3, 2017 , ...

  • PR Newswire3 days ago

    PulteGroup Partners With Lifestyle Personality Rachael Ray To Style New Model Homes

    ATLANTA, Dec. 7, 2016 /PRNewswire/ -- PulteGroup, Inc. (PHM), one of the nation's largest homebuilders, unveiled exciting new model homes outfitted with the stylish furniture designs of television and lifestyle personality Rachael Ray. Furnishings from the Rachael Ray Home collection are now featured at two new communities: Pulte Homes' Shipley Homestead near Baltimore, Maryland and Del Webb Wilmington at Riverlights in Wilmington, North Carolina. To view photo gallery of the Rachael Ray Home collection at Shipley Homestead, click here.

  • PR Newswire10 days ago

    PharmaMar Presents Positive Results With Its Conjugated Antibody MI130110 in CD13-Expressing Tumor-Cells

    PharmaMar (PHM), a world leader in the discovery, development and commercialization of new antitumor compounds of a marine origin, has announced that its antibody-drug conjugate (ADC) has demonstrated a remarkable in vitro antitumoral activity in a CD13, fibrosarcoma positive animal model. MI130110 is formed by a compound of marine origin (PM050489) that has been conjugated to a monoclonal anti-CD13 antibody through a non-hydrolysable linker. Juan Manuel Dominguez, Screening and Biochemistry Departmental Manager of PharmaMar´s Oncology Business Unit, has presented the data on the study entitled "MI130110, a new ADC combining an anti-CD13 antibody and a payload of marine origin shows remarkable in vivo activity" (abstract #397), and carried out in collaboration with both Prof. Francisco Sánchez Madrid´s and Dr Juan Manuel Zapata´s research groups from the Madrid Autónoma University, within the framework of the "Marinmab" project, financed by the Ministry of Economy.